Skip to main content

The Wistar Institute

|

Combination of T Cell Therapy and Targeted Therapy as a Novel Strategy for Therapy-resistant Melanoma with Mutations in the BRAF Gene

PHILADELPHIA and TAMPA, Fla. — (Feb. 14, 2019) — Collaborative research by The Wistar Institute and Moffitt Cancer Center has demonstrated that BRAF targeted therapies render resistant melanoma more sensitive to the attack of killer T cells. This …
Read more
|

Federal Funding Fueled Growth of Wistar Science in 2018

PHILADELPHIA — (Feb. 11, 2019) — The Wistar Institute announces that it was awarded more than $16M in federal research funds in support of its groundbreaking research in cancer, immunology and infectious diseases. Highlights from select awarded gr…
Read more
|

Engineered DNA Vaccine Protects Against Emerging Mayaro Virus Infection

PHILADELPHIA — (Feb. 7, 2019) — A novel, synthetic DNA vaccine developed at The Wistar Institute induces protective immunity against Mayaro virus (MAYV), a mosquito-borne infection endemic to South America, that has the potential to become a globa…
Read more
|

Cullinan Oncology to Develop Novel EBNA1 Inhibitor Discovered by The Wistar Institute

CAMBRIDGE, MA and PHILADELPHIA — January 30, 2019 — Cullinan Oncology, LLC and The Wistar Institute today announced an agreement to accelerate the development of VK-2019, a novel EBNA1 (Epstein-Barr Nuclear Antigen 1) inhibitor discovered by The W…
Read more
|

Scientists of Tomorrow: Carver High School Students Visit Wistar

Scientists at The Wistar Institute had the pleasure of hosting 30 young ladies from George Washington Carver High School of Engineering and Science who take part in the Women of Tomorrow (WOT) Mentor & Scholarship Program. Their visit kicked o…
Read more
|

Induction of Potent Anticancer Immunity Through Rapid Tumor Antigen Identification and Conversion to Personalized Synthetic DNA Vaccines

PHILADELPHIA — (Jan. 24, 2019) — Wistar scientists and collaborators demonstrated the utility of an optimized synthetic DNA vaccine platform for rapidly inducing immunity against unique combinations of tumor neoantigens. These results reveal a dir…
Read more
|

Beauty Beneath the Lens: Nikon Small World Exhibit at Wistar

The opening reception of Nikon Small World, the popular microphotography exhibit hosted every year at Wistar for the past 16 years, reminded us about the beauty hidden within the complexity of life. Guests enjoyed a first view of the gallery and a…
Read more
|

Synthetic DNA’s Role in Advancing Next Generation Checkpoint Inhibitors for Cancer Immunotherapy

An innovative and original synthetic DNA platform created by Dr. David Weiner and team at Wistar’s Vaccine & Immunotherapy Center continues to make great strides in cancer immunotherapy. Monoclonal antibody (mAb) therapy is one of the most suc…
Read more
|

The Opportunity Journey: Innovative Program Prepares Next Generation Scientists

According to Brian Keith, Ph.D., Wistar dean of Biomedical Studies, basic cancer research unravels the complex cellular and genetic mechanisms that underlie disease, and spurs the development of new, rationally designed therapies to ultimately imp…
Read more
|

Using Spider Venom to Make New Therapeutics for Central Nervous  System Disorders

Wistar’s Joseph Salvino, Ph.D., medicinal chemist and professor in the Molecular & Cellular Oncogenesis Program, and scientific director of the Molecular Screening & Protein Expression facility at Wistar, is curren…
Read more